A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
Public ClinicalTrials.gov record NCT07291076. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
ROSETTA HCC-206: An Open-Label, Multi-Center, Randomized Phase 1/2 Study of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC)
Study identification
- NCT ID
- NCT07291076
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Enrollment
- 129 participants
Conditions and interventions
Conditions
Interventions
- Atezolizumab Drug
- Bevacizumab Drug
- Ipilimumab Drug
- Pumitamig Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 15, 2026
- Primary completion
- Oct 14, 2029
- Completion
- Oct 13, 2031
- Last update posted
- May 13, 2026
2026 – 2031
United States locations
- U.S. sites
- 9
- U.S. states
- 7
- U.S. cities
- 7
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution - 0070 | Los Angeles | California | 90064 | Not yet recruiting |
| Local Institution - 0107 | Chicago | Illinois | 60611 | Not yet recruiting |
| John Theurer Cancer Center at Hackensack University Medical Center | Hackensack | New Jersey | 07601-2191 | Recruiting |
| Local Institution - 0100 | Mineola | New York | 11501 | Not yet recruiting |
| Providence Portland Medical Center | Portland | Oregon | 97213 | Recruiting |
| Providence St. Vincent Medical Center | Portland | Oregon | 97225 | Recruiting |
| Tennessee Oncology | Nashville | Tennessee | 37203 | Recruiting |
| Vanderbilt University Medical Center | Nashville | Tennessee | 37232 | Recruiting |
| Local Institution - 0083 | Seattle | Washington | 98109-1024 | Not yet recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 41 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07291076, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 13, 2026 · Synced May 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07291076 live on ClinicalTrials.gov.